Cadonilimab (AK104) is a PD-1/CTLA-4 bispecific antibody that had been approved in China to treat patients with relapsed or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy (17). The gene discussed is CTLA4; the disease is cervical carcinoma.